title: The antiplatelet activity of PMC, a potent alpha-tocopherol analogue, is mediated through inhibition of cyclo-oxygenase.
abstract: PMC, a potent alpha-tocopherol derivative, dose-dependently (5-25 microM) inhibited the ATP-release reaction and platelet aggregation in washed human platelets stimulated by agonists (collagen and ADP). PMC also dose-dependently inhibited the intracellular Ca2+ mobilization, whereas it did not inhibit phosphoinositide breakdown in human platelets stimulated by collagen. PMC (10 and 25 microM) significantly inhibited collagen-stimulated thromboxane A2 (TxA2) formation in human platelets. On the other hand, PMC (25 and 100 microM) did not increase the formation of cyclic AMP or cyclic GMP in platelets. Moreover, PMC (25, 100, and 200 microM) did not affect the thromboxane synthetase activity of aspirin-treated platelet microsomes. PMC (10 and 25 microM) markedly inhibited the exogenous arachidonic acid (100 microM)-induced prostaglandin E2 (PGE2) formation in the presence of imidazole (600 microM) in washed human platelets, indicating that PMC inhibits cyclo-oxygenase activity. We conclude that PMC may exert its anti-platelet aggregation activity by inhibiting cyclooxygenase activity, which leads to reduced prostaglandin formation; this, in turn, is followed by a reduction of TxA2 formation, and finally inhibition of [Ca2+]i mobilization and ATP-release.
authors.affiliation: Graduate Institute of Medical Sciences, Taipei Medical College, Taiwan.
authors.forename: J R
authors.initials: JR
authors.lastname: Sheu
authors.forename: C R
authors.initials: CR
authors.lastname: Lee
authors.forename: C C
authors.initials: CC
authors.lastname: Lin
authors.forename: Y C
authors.initials: YC
authors.lastname: Kan
authors.forename: C H
authors.initials: CH
authors.lastname: Lin
authors.forename: W C
authors.initials: WC
authors.lastname: Hung
authors.forename: Y M
authors.initials: YM
authors.lastname: Lee
authors.forename: M H
authors.initials: MH
authors.lastname: Yen
mesh_terms: D000975:Antioxidants / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D002839:Chromans / Q000494:pharmacology*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D015232:Dinoprostone / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010716:Phosphatidylinositols / Q000378:metabolism; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000187:drug effects; D013929:Thromboxane B2 / Q000096:biosynthesis; D013930:Thromboxane-A Synthase / Q000378:metabolism
chemical_list: D000975:Antioxidants; D002839:Chromans; D016861:Cyclooxygenase Inhibitors; D010716:Phosphatidylinositols; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D013929:Thromboxane B2; C120726:2,2,5,7,8-pentamethyl-6-hydroxychroman; D013930:Thromboxane-A Synthase; D015232:Dinoprostone; D002118:Calcium